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Abstract
Background: Chronic pelvic pain is a common condition among women, and 10 to 30 % of causes originate from
the abdominal wall, and are associated with trigger points. Although little is known about their pathophysiology,
variable methods have been practiced clinically. The purpose of this study was to evaluate the efficacy of local
anaesthetic injections versus ischemic compression via physical therapy for pain relief of abdominal wall trigger
points in women with chronic pelvic pain.
Methods: We conducted a parallel group randomized trial including 30 women with chronic pelvic pain with abdominal
wall trigger points. Subjects were randomly assigned to one of two intervention groups. One group received an injection
of 2 mL 0.5 % lidocaine without a vasoconstrictor into a trigger point. In the other group, ischemic compression
via physical therapy was administered at the trigger points three times, with each session lasting for 60 s, and a
rest period of 30 s between applications. Both treatments were administered during one weekly session for four
weeks. Our primary outcomes were satisfactory clinical response rates and percentages of pain relief. Our secondary
outcomes are pain threshold and tolerance at the trigger points. All subjects were evaluated at baseline and 1, 4, and
12 weeks after the interventions. The study was conducted at a tertiary hospital that was associated with a university
providing assistance predominantly to working class women who were treated by the public health system.
Results: Clinical response rates and pain relief were significantly better at 1, 4, and 12 weeks for those receiving local
anaesthetic injections than ischemic compression via physical therapy. The pain relief of women treated with
local anaesthetic injections progressively improved at 1, 4, and 12 weeks after intervention. In contrast, women
treated with ischemic compression did not show considerable changes in pain relief after intervention. In the
local anaesthetic injection group, pain threshold and tolerance improved with time in the absence of significant
differences between groups.
Conclusion: Lidocaine injection seems to be better for reducing the severity of chronic pelvic pain secondary to
abdominal wall trigger points compared to ischemic compression via physical therapy.
Trial registration: ClinicalTrials.gov NCT00628355. Date of registration: February 25, 2008.
Keywords: Chronic pelvic pain, Ischemic compression, Local anaesthetic injection, Trigger point, Abdominal wall,
Myofascial syndrome
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Background
Chronic pelvic pain (CPP) is a common clinical condi-
tion among women of reproductive age [1], with a nega-
tive impact on the quality of life [2] and significant
socioeconomic repercussions [3]. There are great diffi-
culties in establishing the primary cause of CPP and in
proposing adequate treatment. The conditions that are
most commonly diagnosed in women with CPP are con-
stipation, irritable bowel syndrome, interstitial cystitis/
painful bladder syndrome, endometriosis, and adhesions
[4]. In contrast, 10 to 30 % of cases may be originating
from the trigger points in the abdominal wall muscle [5].
This condition is usually associated with trigger points,
which are usually defined as hyper-irritable sites located
within a taut band of skeletal muscle or fascia. When
compressed, these trigger points cause referred pain,
local tenderness, and autonomic changes [6]. Despite the
variability of the criteria used to diagnose them, they can
be located easily by trained observers [7]. Some authors
have associated them with the abdominal myofascial
pain syndrome [8]. However, it may be almost impos-
sible to distinguish between a true nerve entrapment
and a myofascial trigger point in the rectus abdominis
muscle [7]. Furthermore, they may also be associated
with a visceral pain origin [9] such as endometriosis,
especially when associated with allodynia [8]. Although
little is known about the pathophysiology of the condi-
tion, the use of a local anaesthetic has been recom-
mended as an effective technique for the treatment of
symptomatic active trigger points [10], including abdom-
inal ones [11]. However, few studies have prospectively
evaluated the effects of anaesthetic injections into ab-
dominal wall trigger points [12] and the clear advantages
of this procedure has not been established [13]. Among
others, ischemic compression, has been identified as a
useful non-invasive method for the treatment of trigger
points [14]. However, it remains unknown if ischemia
actually occurs with this intervention. In our country,
non-pharmacological modalities have also been widely
used. These are usually preceded by transcutaneous elec-
tric nervous stimulation (TENS), only for initial analgesia,
as reported in the literature [15]. To our knowledge, there
is no currently available data that shows the superiority of
any one method. Thus, the objective of the present study
was to evaluate the efficacy of local anaesthetic injections
versus ischemic compression for pain relief of abdominal
trigger points in women with CPP.
Methods
Design
This study was a parallel group randomized controlled
trial, which utilized blinded outcome assessors, and an
intention-to-treat analysis. After meeting the eligibility cri-
teria for the study, participants were randomly allocated
by the primary researcher to two experimental groups
according to a computer-generated block randomization.
Registration
The study followed the Declaration of Helsinki and was
approved by our Research Ethics Committee (process
number:10272/2007, University Hospital, Ribeirão Preto
Medical School). All subjects signed the informed consent
prior to participation. This study was registered on Clini-
calTrials.gov- NCT00628355 on date February 25, 2008.
Setting
Center of Chronic Pelvic Pain and Gynecologic Endos-
copy of the Universitary Hospital, Ribeirão Preto Med-
ical School, University of Sao Paulo.
Participants
Thirty women of reproductive age with CPP and trigger
points of the inferior abdominal wall were included in
the study. The flow of subjects and location of the trig-
ger points are presented in Figs. 1 and 2, respectively.
We excluded women with anticoagulation or bleeding
disorders; local or systemic infections; an allergy to
anaesthetic agents; acute muscle trauma; extreme fear of
needles; a history of chronic musculoskeletal pain com-
plaints such as fibromyalgia, chronic fatigue syndrome,
and neurologic or neuropsychiatric conditions; and
hypertension or diabetes. We also excluded those who
had ingested aspirin within three days of the injection
and users of antidepressants or corticosteroids that were
administered for at least 30 days. All patients with sus-
pected endometriosis and/or irritable bowel syndrome,
interstitial cystitis, and painful bladder syndrome were
also excluded. Pelvic/abdominal ultrasound was used to
exclude the presence of endometriomas or hernias.
All women were evaluated at baseline and 1, 4, and
12 weeks after the intervention, and were instructed to
perform pharmacological washout of central analgesics
and/or NSAIDs for at least 72 h prior to all clinical
evaluations.
Interview and examination
All women completed a clinical evaluation. Each woman
filled out a form containing the hospital anxiety and
depression scale (HAD), visual analogue scale (VAS),
McGill Pain Index, and a World Health Organization in-
strument to assess quality of life (WHOQoL).
Measurements
Pain threshold (minimal pressure that causes pain or
discomfort) and pain tolerance (maximal pressure that
the patient can withstand) were measured with an alg-
ometer, which is a 1 cm diameter disk attached to the
plunger of a pressure gauge. The dial of the gauge is
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calibrated in kg/cm2, with a measuring capacity of 5 kg
(Instrutherm Ltda, São Paulo, Brazil). The algometer
was placed perpendicularly on the trigger point, and the
pressure was increased gradually (0.1 kgf/s) until the
patient reported the first painful discomfort (threshold)
and until the maximum stimulus withstood (tolerance).
Two measurements were made with an interval of three
minutes and the mean value was used for analysis.
Interventions
Group 1: Local anaesthetic injection of 2 mL 0.5 % lido-
caine without a vasoconstrictor, directly and perpendicu-
larly applied into the trigger point. No direct pressure
was applied after the injection was administered weekly
for four weeks.
Group 2: Ischemic compression was applied by sus-
tained pressure on the trigger point. This pressure was
sufficient to cause moderate local pain evoking the
referred pain pattern [16]. This therapy was applied
three times, lasting for 60 s for each session, with a rest
period of 30 s between applications [17] for four sessions
weekly. The compression was preceded by TENS, which
delivers electric stimulation lasting for 30 min using a
Dualpex 961 device with a frequency of 100 Hz, pulse of
250 μs, and intensity according to the pain threshold of
the patient in order to promote initial analgesia [18].
Outcomes
Primary outcomes: satisfactory clinical response rate
(defined by the Health Ministry of Brazil as a VAS re-
duction of at least 50 % or as a significant subjective
impact on daily life activities (http://bvsms.saude.gov.br/
bvs/saudelegis/sas/2012/prt1083_02_10_2012.html).
Secondary outcomes: proportion of pain relief ([VAS
before and after treatment]/[VAS before treatment]),
threshold, and tolerance on the trigger point.
Sample size
Sample size estimation was based on the differences
between proportions in the satisfactory clinical response
rate between the two groups. We considered a 30 %
relative change in the between groups rate to be
Women admitted and assessed for eligibility
(n=212)
Assessed for eligibility
(n = 38)
Randomised (n=30)
Local anesthesic injection
(n=15)
Follow-up (12 weeks)
(n =14)
Discontinued 
intervention (n=1)
Ischemic compression (preceded by TENS)
(n =15)
Follow-up (12 weeks)
(n =14)
Discontinued 
intervention (n=1)
Excluded (n=8)
- severe dysmenorrhea (n=5)
- extreme fear of needles (n=2)
- allergy declared to anesthetic agents (n=1)
Excluded (n=174)
-other causes of chronic pelvic pain
Fig. 1 Flowchart of the study
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clinically significant. In order to have 90 % power to de-
tect this change with an overall two-sided type I error
rate of 5 %, this trial required a total of 60 subjects, or
30 for each group. This sample size was estimated using
an online calculator (lee.dante.br).
The trial design included an interim analysis in order
to determine if the trial needed to be discontinued early
for efficacy or futility. Based on the results of the interim
analysis, the study was stopped early, after including five
blocks of six subjects each, because we considered the
clinical response rate of intervention 2 to be significantly
lower than that of intervention 1, after follow-up. At the
time of the interim analysis, 15 subjects were enrolled in
each group. Based on the O’Brien-Fleming approach
group sequential boundary, the significance level for the
primary end point was 0.025.
Fig. 2 Location of the trigger points. Notes: # umbilical scar; * abdominal rectus edge; dark gray: trigger points from the group 1; soft gray: trigger points
from the group 2
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Randomization
Sequence generation
Block randomization, consisting of ten blocks of six sub-
jects each, with three patients in each group of treatment,
was generated online (http://www.randomization.com).
Control of bias
The first evaluation and the clinical diagnosis were per-
formed by two experts (OBPN, JCRS) using the criteria
developed by Travell and Simons [8], in order to recognize
active trigger points. A third and fourth researcher, who
were blinded to all clinical data except for the location of
the trigger point, performed either intervention 1 or 2. An
independent observer, who was blind to the previous clin-
ical data and therapy modality, performed the follow-up
measurements. A professional who was blinded to all in-
formation performed the statistical analysis.
Statistical analysis
Normal distribution of the data was determined using the
Shapiro-Wilk test. Once normal distribution was con-
firmed, the comparison of quantitative variables between
different groups was performed by the t-test. When normal
distribution was not confirmed, the analysis was performed
using the Wilcoxon test. The Chi-square/Fisher’s exact test
was used, when appropriate, to analyse nominal variables.
Primary outcome was analysis using generalized linear
mixed models. This model was implemented in the SAS
program software using the PROC GENMOD. This model
estimates the relative risk, independent of time, to verify
the relationship between clinical response rate and group.
It also estimated the relative risk within each study period.
All statistical tests were two-sided. The significance level
for the primary end point was adjusted for a single interim
analysis to 0.025. Otherwise, we considered P values of
less than 0.05 to indicate statistical significance.
In order to compare the times for each group separately,
a nonparametric mixed-effects model for longitudinal data
[19] was proposed in the analysis of the secondary end-
points. To compare the times for each group separately,
we can apply multiple comparisons with Bonferroni
adjustment. To compare the groups at each time point
separately, the Mann–Whitney test, (a nonparametric
technique), was used to compare distributions of two or
more groups that require no assumptions about the distri-
bution of data. The level of significance was considered as
5 %. The analysis was conducted by the package nparLD
using the R software. Additional file 1: Supplementary
material is disponible.
Results
Participant flow
The numbers of participants who were assigned, re-
ceived intended treatment, and were analysed for the
primary outcome are presented in Fig. 1. A total of 212
women with CPP were screened at the hospital for study
eligibility. One hundred seventy-four cases were excluded
after other diagnostic exams for CPP were performed.
Eight women with severe dysmenorrhea were excluded
due suspected endometriosis. Two patients only attended
the first treatment session. Telephone, letter, and e-mail
contact was attempted without success. Nevertheless,
these patients were included in the analysis.
Recruitment
Recruitment was performed between February 2008 and
March 2010, and patients were followed for 12 weeks.
The trial was stopped early because we observed that
the clinical response rate was significantly better in one
of the arms. The local ethics committee and clinical staff
recommended discontinuation of the study.
Baseline data
Table 1 shows the baseline demographic and clinical
characteristics of each group.
Numbers analysed
Satisfactory clinical response rate
Clinical response rates were better for the local anaes-
thetic injection than for ischemic compression (80.0 %
(12/15) vs. 40.0 % (6/15) (p = 0.018) 1 week after treat-
ment; 80.0 % (12/15) vs. 40.0 % (6/15) (p = 0.018) 4 weeks
after treatment; and 73.3 % (n = 11/15) vs. 13.3 % (2/15)
(p = 0.00006) 12 weeks after treatment). The estimated
relative risk showed that the anaesthetic injection demon-
strated approximately 3.8 times better clinical response
rates compared to ischemic compression, independent of
time (Table 2).
Pain relief
The pain relief of women treated with local anaesthetic
injections progressively improved 1, 4, and 12 weeks
after intervention. In contrast, women treated with is-
chemic compression did not show a considerable change
in pain relief after intervention (Table 3). The percent
rate of improvement (1, 4 and 12 weeks after interven-
tion) was progressively higher in group 1 (reduction of
45.3, 60.2 and 69.9 % of VAS, respectively) (p = 0.03)
compared to group 2 (reduction of 18.7 %, 9.2 %).
Although the differences between groups in the vari-
ous time points were not significant, pain threshold and
tolerance improved progressively in the women who re-
ceived the local anaesthetic injection (Table 4).
Harmful or unintended effects
There were no important harmful or unintended effects.
However, two patients in Group 1 (local anaesthetic injec-
tion) presented with ecchymoses (3.4 cm and 5.1 cm of
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extension) that resolved spontaneously within 4 and
6 weeks, respectively.
Discussion
Synthesis
In the present study, we observed that local anaesthetic
injections were superior to ischemic compression, and
resulted in progressive improvements in pain relief.
Despite the absence of statistical differences with the
compression group, we observed that the local pain
threshold and tolerance of women submitted to a local
anaesthetic injections improved throughout the follow-
up period and until the end of treatment.
Interpretation
To our knowledge, this is the first randomized trial dem-
onstrating the superiority of a local anaesthetic for the
treatment of the trigger points in the inferior abdominal
wall of women with chronic pelvic pain even though this
method has been proven to be effective in the treatment
of other myofascial syndromes [20], and is similar to the
effects of the lidocaine patch [21].
The effects of acute anaesthesia that are promoted by
local anaesthetics are well known, and are believed to
occur by interrupting nerve excitation and conduction
by direct interaction with voltage-gated Na channels.
Reduction of inflammation and activation TRPV1 e
TRPA1 might explain long term effects of lidocaine
[22]. However, we observed that, even after the injec-
tions were stopped, the pain relief reported by the sub-
jects who received this intervention was significantly
progressive. The present study does not permit us to
reach precise conclusions about the mechanisms asso-
ciated with this continued long-term effect. It is likely
that this effect can be explained by the affinity of lido-
caine with the Na channel, since it is known that the
drug has a low affinity for the channels, when they are
in the standby mode and demonstrated higher affinity
when they are open and/inactivated [23]. The applica-
tion of anaesthetics may be associated with the occur-
rence of skeletal muscle tissue or neural damage [24].
Nevertheless, muscle injury is usually reversible and
tissue regeneration occurs within 4 to 6 weeks [25].
Although neurotoxicity may justify the progressive ef-
fect of local anaesthetic injections, we did not identify
other clinical signs during the study period, such as
dysesthesia, paresthesia, or sensorimotor deficits that
differ from those reported at baseline [26]. Although we
tend to associate pain relief to the presence of a local an-
aesthetic, we cannot overlook the potential effect of dry
needling, it has been shown to be capable to evoking anti-
nociceptive effects by segmental modulation. Although
Table 1 Baseline demographic and clinical characteristics for each group
Variables Group 1 (n = 15) Group 2 (n = 15) p
Age, y [mean ± sd] 38.5 ± 2.8 36.8 ± 3.2 .132
BMI, Kg.m−2 [mean ± sd] 28.8 ± 4.1 25.0 ± 3.8 .129
Parity [median, range] 1 (0–6) 1 (0–3) .700
Abdominal surgeries [median, range] 1 (0–4) 1 (0–3) 820
Measures pretreatment
VAS, mm [median, interquartile] 54 (49–90) 67 (56–75) .505
McGill [median, interquartile] 29.5 (13–38) 35.5 (21–42) .434
Time of symptoms [median, interquartile] 31 (8–76) 38 (9–63) .331
Pain threshold, kg.cm−2 [mean ± sd] 1.05 ± 0.49 1.04 ± 1.30 .988
Pain tolerance, kg.cm−2 [mean ± sd] 1.90 ± 0.72 1.81 ± 1.62 .864
HAD anxiety [median, interquartile] 11 (8–16) 13 (10–17) .187
HAD depression [median, interquartile] 10.5 (5–14) 10.5 (8–13) .853
WHOQoL [mean ± sd] 53.0 ± 10.3 49.2 ± 14.2 .448
Notes. Group 1: local anesthetic injection; Group 2: ischemic compression via physical therapy; y years, sd standard deviation; interquartile: 25–75 %, BMI body
mass index; time of symptoms in months, HAD hospital anxiety depression scale, WHOQoL World Health Organization quality of life
Table 2 Estimated relative risk between groups within each time and independent of time (adjust)
Time Group 1 (n = 15) Group 2 (n = 15) RR crude (IC 95 %) RR adjust (IC 95 %)a
1st week 12 (80,00 %) 6 (40,00 %) 2 (1,02; 3,91) 3,8 (1,17; 8,08)
4th week 12 (80,00 %) 6 (40,00 %) 2 (1,02; 3,91)
12th week 11 (73,33 %) 2 (13,33 %) 5,5 (1,46; 20,71)
aRelative risk (RR) adjusting by generalized linear mixed models
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this effect seems to be considerable for a few minutes
[27], it could not completely explain our results. Never-
theless, the effectiveness of the dry needle seems to
depend on the integrity of the afferent and spinal cord
circuitry [28], which may involve supraspinal pain con-
trol via midbrain periaqueductal grey activation, among
others. Some studies have demonstrated that this is an
effective and safe method for the treatment of trigger
points [29], which may present with effects similar to
placebo [30].
In contrast, even though we had observed a consider-
able improvement of pain at the trigger points immedi-
ately after the ischemic compression (preceded by
TENS), this improvement was not maintained until
follow-up. Recent literature studies have demonstrated
changes in blood flow and cell metabolism at a myofas-
cial trigger point after release with ischemic compression
[31], and improvement of pain secondary to myofascial
syndromes after ischemic compression [32]. However,
the studies did not involve sufficiently long follow-up
times for the clearance of the placebo effects of the
method. TENS, in turn, has shown positive short-term
effects on trigger points, but not during medium or
long-term follow-up [33]. At present, we understand
that it is not possible to recommend ischemic compres-
sion as a first-line therapeutic modality for the treatment
of trigger points of the abdominal wall.
Limitations
Although the present results demonstrate the superiority
of one of the methods, we have to recognize that the
early interruption of the trial is a limiting factor. This
may increase the possibility of an alpha error, which
favour the overestimation of the effect. Although cur-
rently available empirical evidence suggests that early
interrupted clinical trials overestimate the effects of new
treatments and that the reasons used to justify interrupt-
ing the trial are often not sufficiently specified [34], after
a judicious evaluation by our physician and the ethics
committee staff, we believe that interrupting the trial
was an ethical obligation.
Conclusions
The results of the present study suggest that local anaes-
thetic injection is superior to ischemic compression for
the treatment of abdominal wall trigger points. Since we
selectively excluded subjects with comorbidities and other
causes of chronic pelvic pain, we cannot confirm that this
intervention, compared to those that had been applied by
experts, works in the more complex “real-life” setting.
Thus, future pragmatic clinical trials are needed in order
to confirm the effectiveness of this method in a wider
variety of circumstances as well as assess whether it is
better compared to techniques such as dry needling or
acupuncture, for example.
Table 3 Evaluation of percentage of pain relief between groups and intra group (between different times of follow-up)
Groups VAS Baseline %
[median(range)]
VAS 1st week %
[median(range)]
VAS 4th week %
[median(range)]
VAS 12th week %
[median(range)]
Pd
Group
1
0.0 [54 (49–90)] −45.3a [30.5 (8–58)] −60.2b [10 (0–49)] −69.9c [8 (0–39)] .03
Group
2
0.0 [67 (56–75)] −18.7a [50 (47–54)] −9.2b [60 (42–61)] −8.5c [56 (42–67)] .47
P .50 .08 <.01 <.01 —
Notes: all measurements are represented by percentage of pain relief (%VAS) and by median and 25–75 % quartiles (range) of VAS. The minus signal (−) signify
reduction of pain scores. Post test for threshold at Group 1: a vs b = .06; a vs c = .01; b vs c = .10; d time effect
Table 4 Evaluation of measurements of pain threshold and pain tolerance between groups and intra group (between different
times of follow-up)
Groups Baseline 1st week 4th week 12th week Pd
Threshold
Group 1 1.00 (0.85–1.31) 0.97a (0.88–1.04) 1.44b (1.08–1.62) 1.37c (1.26–1.49) <.01
Group 2 0.72 (0.57–1.06) 1.21 (0.84–1.82) 1.08 (0.92–1.13) 1.10 (0.95–1.27) .76
p .99 .32 .13 .97
Tolerance
Group 1 1.87 (1.42–2.24) 1.60a (1.46–1.72) 2.00b (1.73–2.23) 2.23c (2.22–2.24) <.01
Group 2 1.44 (1.04–1.92) 1.91 (1.53–2.44) 1.51 (1.22–1.87) 1.46 (1.32–1.49) .52
p .86 .67 .09 .24
Notes: all measurements are represented by median and 25–75 % quartiles. Post test for threshold at Group 1: a vs b < .01; a vs c < .01; b vs c = .02; Post test for
tolerance at Group2: a vs b < .03; a vs c < .01; b vs c = .67; dtime effect
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